0000950170-24-002280.txt : 20240104 0000950170-24-002280.hdr.sgml : 20240104 20240104214944 ACCESSION NUMBER: 0000950170-24-002280 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240103 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brumm Joshua T CENTRAL INDEX KEY: 0001528826 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24514346 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-01-03 0001818794 Dyne Therapeutics, Inc. DYN 0001528826 Brumm Joshua T 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false CEO & President true Common Stock 2024-01-03 4 M false 51183 1.03 A 636154 D Common Stock 2024-01-03 4 S false 15382 18.34 D 620772 D Common Stock 2024-01-03 4 S false 19775 19.03 D 600997 D Common Stock 2024-01-03 4 S false 16026 20.50 D 584971 D Common Stock 2024-01-04 4 M false 18536 1.03 A 603507 D Common Stock 2024-01-04 4 M false 200000 5.54 A 803507 D Common Stock 2024-01-04 4 S false 180235 18.40 D 623272 D Common Stock 2024-01-04 4 S false 38301 19.05 D 584971 D Stock option (right to buy) 1.03 2024-01-03 4 M false 51183 0 D 2030-01-05 Common Stock 51183 18536 D Stock option (right to buy) 1.03 2024-01-04 4 M false 18536 0 D 2030-01-05 Common Stock 18536 0 D Stock option (right to buy) 5.54 2024-01-04 4 M false 200000 0 D 2030-07-30 Common Stock 200000 107863 D Includes 552,729 unvested RSUs. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.58, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.93, inclusive. The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter. The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024. /s/ Richard Scalzo, Attorney-in-Fact 2024-01-04